SERUM TESTOSTERONE AS A MARKER OF RESPONSE TO ANDROGEN DEPRIVATION THERAPY IN METASTATIC PROSTATE CANCER
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i8.48075Keywords:
Prostate-specific antigen, S. testosterone, Metastatic prostate cancer, AndrogenAbstract
Objective: Prostate cancer (PCa) is the second most widespread cause of cancer and the sixth foremost cause of cancer death among men worldwide. The sustained presence of particular hormones and growth factors stimulates the prostate, such as other sex accessory tissues, in its growth, maintenance, and secretory function. In the current study, we investigated the association of serum testosterone level and prostate-specific antigen (PSA) level before androgen deprivation therapy in metastatic PCa (mPCa) treated with hormone therapy.
Methods: This retrospective cohort was conducted from July 2017 to December 2019 in the Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh on patients diagnosed with mPCa of age >40 years. Total serum testosterone was measured by Electro chemiluminescent immune assay before the treatment. PSA in serum specimens was evaluated.
Results: The mean age was 67.74±8.12 (55–80) years. Serum PSA levels at baseline, 3 months were 530.98±617.28 (ng/dL), and 56.31±89.04 (ng/dL), respectively. The baseline S. testosterone was 288.89±246.53 (ng/mL). Weak negative correlation between the two (p=0.051) As the serum testosterone levels decrease the PSA levels increase and vice-versa. Positive correlation between baseline testosterone and PSA decline (p<0.05). On histopathology, 58.7% (n=71) of the patients had perineural involvement, while 41.3% (n=50) did not have perineural involvement.
Conclusion: We conclude that the effect of testosterone might have a possible role in the assessment of treatment response as assessed by PSA. However, the exact implication and its role in disease assessment need to be examined in a larger prospective cohort.
Downloads
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan. Int J Cancer 2015;136:E359-86.
Mohler J, Bahnson RR, Boston B, Busby JE, Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
Nakhla AM, Rosner W. Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of sex hormone-binding globulin. Endocrinology 1996;137:4126-9.
Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987;80:281-5.
Vergho DC, Heine K, Wolff JM. The role of PSA in diagnosis of prostate cancer and its recurrence. Pathologe 2005;26:473-8.
Huggins C, et al. Studies on prostatic cancer: The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of prostate. J Urol.
Morote J, Ramirez C, Gomez E, Planas J, Raventos CX, Torres IM, et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 2009;104:486-9.
Jemal A, Siegal R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
Araujo AB, Esche GR, Kupelian V, Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241-7.
Walsh TJ, Shores MM, Krakauer CA, Forsberg CW, Fox AE, Moore KP, et al. Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels. PLoS One 2018;13:e0199194.
Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate IV Anti-androgen treated patients. J Urol 1989;141:1088.
Maatman TJ. The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate. J Urol 1989;141:1378-80.
Yamamoto S, Ito T, Akiyama A, Aizawa T, Miki M, Tachibana M. M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL. Int J Urol 2001;8:374-9.
Sella A, Konichezky M, Flex D, Sulkes A, Baniel J. Low PSA metastatic androgen-independent prostate cancer. Eur Urol 2000;38:250-4.
Ost P, Bossi A, Decaestecker K, Meerleer G, Giannarini G, Karnes R, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature. Eur Urol 2015;67:852-63.
Khoo V. Is there another bite of the cherry The case for radical local therapy for oligometastatic disease in prostate cancer. Eur Urol 2016;69:13-4.
Mikkola AK, Aro JL, Rannikko SA, Salo JO. Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. Prostate 1999;39:175-81.
Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgenteler A, et al. Testosterone and prostate cancer: Revising old paradigms. Eur Oncol 2009;56:48-56.
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al. Prevalence of prostate cancer on autopsy: Cross sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 2013;105:1050-8.
Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.
Chodak GW, Vogelzang NJ, Caplan RJ, Soloway MS, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 1991;265:618-21.
Dai B, Qu Y, Kong Y, Ye D, Yao X, Zhang S, et al. Low pre-treatment serum total testosterone is associated with a high incidence of Gleason score 8 10 disease in prostatectomy specimens: Data from ethnic Chinese patients with localized prostate cancer. BJU Int 2012;110:E667-72.
Furuya Y, Nozaki T, Nagakawa O, Fuse H. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. Endocr J 2002;49:85-90.
Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008;72:1240-5.
Porcaro AB, Petroziello A, Brunelli M, De Luyk N, Cacciamani G, Corsi P, et al. High testosterone preoperative plasma levels independently predict biopsy gleason score upgrading in men with prostate cancer undergoing radical prostatectomy. Urol Int 2016;96:470-8.
Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-20.
Iversen P, Rasnussen F, Christensen IJ. Serum testosterone as a prognostic factor in patients with advanced prostatic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 1994;157:41-7.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Bharat Bhushan Bamaniya, Dr Ravimohan, Dr Bora, Aditya Prakash Sharma, Sharawan Kumar Singh, Ashu Rastogi
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
